Illumina Genome Analyzer Selected by Internationally Recognized Medical Center to Sequence 50 Human Genomes

http://investor.illumina.com/phoenix.zhtml?c=121127&p=iIllumina (NASDAQ:ILMN) today announced that researchers at Duke University Medical Center will utilize Illumina’s Genome Analyzer to study the resistance to HIV infection among 50 individuals that were highly exposed to the virus, but who remain uninfected. Duke University researchers will sequence the complete genome of at least 50 individuals with the desired phenotype.

Source: Illumina